

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



INTERNATIONAL PATENT COOPERATION TREATY (PCT)

(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72709 A1

(51) International Patent Classification⁷: C07D 213/30,
213/26, 213/32, 239/26, 277/24, 213/61, 213/68, A61K
31/425, 31/4409, 31/505, 31/44

(74) Agents: SALES, James, J. et al.; Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285 (US).

(21) International Application Number: PCT/US01/05817

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 19 March 2001 (19.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00500050.0 29 March 2000 (29.03.2000) ES

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BAKER, Stephen,
Richard [GB/GB]; Eli Lilly and Company Limited,
Kingsclere Road, Basingstoke, Hampshire RG21 2XA
(GB). BLEAKMAN, David [GB/US]; 720 Eagle Creek
Court, Zionsville, IN 46077 (US). LAMAS-PETEIRA,
Carlos [ES/ES]; Lilly, S.A., Avda. Industria, 30, 28108
Alcobendas-Madrid (ES).



WO 01/72709 A1

(54) Title: NAPHTALENE DERIVATIVES AND THEIR PHARMACEUTICAL USE



(57) Abstract: Use of compounds of the formula (I) where A, E, R¹, R², p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.

- 1 -

NAPHTHALENE DERIVATIVES AND THEIR PHARMACEUTICAL USE

The present invention relates to certain naphthalene derivatives which are useful as pharmaceuticals. More particularly it relates to a new pharmaceutical use for novel and known naphthalene derivatives, to novel naphthalene derivatives, to a process for preparing the novel naphthalene derivatives and to a pharmaceutical composition comprising naphthalene derivatives.

10 L-Glutamate mediates excitatory neurotransmission in the mammalian central nervous system through its action at glutamate receptors. There are two broad classes of glutamate receptors, known as the ionotropic glutamate receptors and the metabotropic glutamate receptors. Within
15 the class of ionotropic glutamate receptor are three classes, known as the N-methyl-D-aspartate (NMDA), (R,S)-2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoate (AMPA) and kainate (KA) receptors. Molecular biological studies have established that AMPA receptors are composed of
20 subunits (GluR1-4) that can assemble to form functional channels. Five kainate receptors, classified as either high affinity (KA1 and KA2) or low affinity (GluR5, GluR6 and GluR7) kainate receptors have been identified. (Bleakman et al, *Molecular Pharmacology*, 1996, Vol. 49, No. 4, pgs. 581-
25 585 and Hollmann, M., and Heinemann, S., Cloned Glutamate Receptors, *Ann. Rev. Neurosci.* 1994, 17: 31-108).

J. Org. Chem., Fozard and Bradsher, vol. 31, pag. 3683-5 describes the synthesis of 2-[2-(2-(1-chloro)naphthyl)vinyl]pyridine.

30 J. Organometallic Chem., 108, (1976), 175-181 describes the synthesis of 2-[2-(2-(1-bromo)naphthyl)vinyl]pyridine.

JCS Perkins II, 1975, 1712-5 discloses unsubstituted naphthylvinylpyridine analogues.

- 2 -

J. Med. Chem., 1971, vol. 14, 315-22 discloses 4-[2-(2-naphthyl)vinyl]pyridine useful in the inhibition of brain choline transferase.


J. Med. Chem., 1972, vol. 15, 1168-71 discloses 4-[2-(2-naphthyl)vinyl]-2-nitropyridine which possess an
5 anthelmintic effect.

J. Med. Chem., 1969, vol. 12, 134-38 discloses 4-[2-(2-naphthyl)vinyl]pyridine and 4-[2-(2-naphthyl)acetyl]pyridine useful as choline
10 acetyltransferase inhibitors.

J.O.C., vol. 49, 1984, 2546-51 discloses 4-[2-(2-(6-dialkylamino)naphthyl)vinyl]pyridine derivatives useful as intermediates for the synthesis of charge-shift probes of membrane potential.

J. Med. Chem., 1993, vol 36, 1278-83 discloses 4-[2-(2-naphthyl)vinyl]pyridine and 4-[2-(2-naphthyl)ethyl]pyridine
15 useful as substrates of Monooxidase A & B.

Accordingly, the present invention provides the use of
20 a compound of general formula:



where p is 0 to 4, q is 0 to 3,

25 -A- represents a group $-\text{CHR}^3-\text{CHR}^4-$, $-\text{CR}^5=\text{CR}^6-$, $-\text{C}\equiv\text{C}$, or $-\text{COO}-$,

wherein R^3 is hydrogen or hydroxy,

R^4 , R^5 and R^6 are each independently hydrogen or C_1-C_6 alkyl, a substituted or unsubstituted phenyl, carboxy(C_1-

- 3 -

C₆)alkyl or cyano;

-E represents a substituted or unsubstituted heterocycle;

R¹ and R² are each independently selected from C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy, nitro, cyano, C₁-C₆ alkylthio, halogen, trifluoromethyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted benzyl or a group represented by -O-(CH₂)_{m'}-Y, in which Y represents C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, a substituted or unsubstituted phenyl, C₁-C₆ alkoxy, and m' is 0 or 1;

or a pharmaceutically acceptable salt or ester thereof, provided that when m' represents 0, Y represents C₃-C₆ cycloalkyl or a substituted or unsubstituted phenyl; for the manufacture of a medicament for the treatment of a condition indicating treatment with a GluR6 antagonist.

The present invention also provides a method of antagonising the action of L-glutamate at GluR6 receptors in a warm blooded mammal requiring such treatment, which comprises administering to said mammal an effective amount of a compound of general formula I, or a pharmaceutically acceptable salt thereof as defined hereinabove.

As described hereinabove, compounds of formula I have been found to be antagonists of L-glutamate at GluR6 receptors. They have further been found to be non-competitive antagonists. In other words, their antagonist effect has been found to be unaffected by increasing concentration of agonist. Furthermore, it has been found that their action is both use-dependent and voltage-dependent. This term relates to compound activity at ion channels where compound activity appears dependent upon ion channel opening and/or ion influx through the channel. Thus

- 4 -

the ability of the compound to block the channel is enabled by the opening of the channel. Likewise, reversal of the compound inhibition is enabled by repeat application of agonist (glutamate). These are features compounds that act as 'use-dependent molecules' such that the accumulation of inhibition with repetitive stimuli has been termed use-dependence (Courtney, K.R., J. Pharm. Expt. Ther. 195, 225-236, 1975). In particular, it has been found that the compounds exhibit a slow onset of inhibition which develops with agonist-dependent ion channel activation and reverses at a rate dependent upon agonist-dependent activation. Inhibition has also been observed at hyperpolarised (negative) membrane potentials during ion influx, but not at depolarised (positive) potentials during ion efflux under whole cell voltage clamp recording conditions. Use-dependence molecules may have therapeutic advantage inasmuch that compound activity may (i) be preferentially restricted to neurons that are excited by glutamate actions at GluR6 in particular CNS disorders and/or (ii) have a duration of action enhanced (longer biological half life) where reversal of inhibition dependent upon ion channel opening.

A variety of physiological functions have been shown to be subject to influence by excessive or inappropriate stimulation of excitatory amino acid transmission. The formula I compounds of the present invention are believed, through their action as GluR6 antagonists, to have the ability to treat a variety of neurological disorders in mammals associated with this condition, including acute neurological disorders such as cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord lesions due to trauma or infarction/ischaemia or inflammation, head trauma, perinatal hypoxia, cardiac arrest, and hypoglycemic neuronal damage,

- 5 -

and chronic neurological disorders, such as Alzheimer's disease, Huntington's Chorea, inherited ataxias, amyotrophic lateral sclerosis, AIDS-induced dementia, ocular damage and retinopathy, cognitive disorders, Parkinson's Disease, drug-
5 induced Parkinsonism and essential tremor. The present invention also provides methods for treating these disorders which comprises administering to a patient in need thereof an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

10 The formula I compounds of the present invention are also believed, through their action as GluR6 antagonists, to have the ability to treat a variety of other neurological disorders in mammals that are associated with glutamate dysfunction, including muscular spasms, convulsions (such as
15 epilepsy), spasticity, migraine headache, cluster headache, chronic daily headache, urinary incontinence, psychosis, (such as schizophrenia or bipolar disorder), post traumatic stress disorder, depression, drug tolerance and withdrawal (such as alcohol, nicotine, opiates and benzodiazepines),
20 drug intoxication, metabolic derangement, anxiety and anxiety related disorders such as post-traumatic stress syndrome, emesis, brain edema, pain (acute and chronic, neuropathic or retractable, post traumatic pain), and tardive dyskinesia. Therefore, the present invention also
25 provides methods for treating these disorders which comprise administering to a patient in need thereof an effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof.

The term "treating" for purposes of the present
30 invention, includes prophylaxis, amelioration or elimination of a named condition once the condition has been established.

The term "patient" for purposes of the present invention is defined as any warm blooded animal such as, but

- 6 -

not limited to, a mouse, guinea pig, dog, horse, or human. Preferably, the patient is human.

It will be appreciated that the compounds of formula (I) may contain one or more asymmetric carbon atoms, especially wherein R^3 is OH. Accordingly, the compounds of the invention may exist in and be isolated in enantiomerically pure form, in racemic form, or in a diastereoisomeric mixture. The present invention includes all such forms.

In the above general formula, the term C_1-C_6 alkyl group means a straight or branched alkyl group containing from 1 to 6 carbon atoms. It includes the terms C_1-C_5 alkyl and C_1-C_4 alkyl. Examples of particular values for a C_1-C_6 alkyl group are methyl, ethyl, propyl, isopropyl, butyl and isobutyl, and is preferably methyl or ethyl.

Examples of particular values for a C_2-C_6 alkenyl group include, vinyl, prop-2-enyl, but-3-enyl, pent-4-enyl and isopropenyl, and an alkenyl group can contain more than one double bond. A preferred alkenyl group is vinyl.

Examples of particular values for a C_2-C_6 alkynyl group include, prop-2-ynyl, but-3-ynyl and pent-4-ynyl, and is preferably of the formula $R^1C\equiv C-$ where R^1 is C_1-C_4 alkyl.

Examples of particular values for a C_3-C_6 cycloalkyl group are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and these groups may optionally be substituted by one or more C_1-C_4 alkyl, for example methyl, or ethyl substituents.

The terms C_1-C_6 alkoxy or a C_1-C_6 alkylthio are an alkyl group linked to an oxygen or a sulphur atom, where the alkyl is as defined above. Examples of particular values for a C_1-

- 7 -

C₆ alkoxy or a C₁-C₆ alkylthio group include methoxy, ethoxy, thiomethyl or thioethyl.

Examples of particular values for halogen include fluoro, chloro and bromo, preferably fluoro or chloro.

The term C₁-C₆ acylamino means a C₁-C₆ alkyl group linked to an amide group, where the C₁-C₆ alkyl is as defined above. It includes a group of the formula R^{IV}-NH-CO- where R^{IV} is C₁-C₅ alkyl. An Example of a particular value of a C₁-C₆ acylamino group includes acetamide.

In the above general formula, a substituted phenyl, benzyl or phenoxy group is substituted by one or more, for example from one to three substituents, selected from C₁-C₆ alkyl, especially methyl, C₁-C₆ alkoxy, especially methoxy and ethoxy, carboxy, hydroxy, cyano, halogen, especially bromo, chloro and fluoro, trifluoromethyl, nitro, amino, C₁-C₆ acylamino, C₁-C₆ alkylthio, a unsubstituted or phenyl substituted by one to three substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or halogen, and a unsubstituted or phenoxy substituted by one to three substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl or halogen.


25

A substituted heterocycle includes a five, six or seven membered ring containing one or more heteroatoms selected from N, O or S, and can be saturated or unsaturated. When a heterocycle contains a nitrogen atom, it can be linked to a carbon atom in the ring and it can also be linked through the nitrogen atom. Examples of particular values for

30

- 8 -

heterocycle include compounds of the formula:



wherein R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰,
 10 R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and
 R³² are each independently selected from C₁-C₆ alkyl,
 especially methyl, C₁-C₆ alkoxy, especially methoxy and
 ethoxy, carboxy, hydroxy, cyano, halogen, especially bromo,
 chloro and fluoro, trifluoromethyl, nitro, amino, C₁-C₆
 15 acylamino, C₁-C₆ alkylthio, a substituted or unsubstituted
 phenyl, a substituted or unsubstituted benzyl and a
 substituted or unsubstituted phenoxy.

- 9 -

Examples of particular values for R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² include C₁-C₆ alkyl, especially methyl, C₁-C₆ alkoxy, especially methoxy, halogen, especially chloro and fluoro, trifluoromethyl, amino, a substituted or unsubstituted phenyl, and a substituted or unsubstituted phenoxy.

In the compounds of formula I,

10 -A- preferably represents -CHR³-CHR⁴- or -CR⁵=CR⁶-. Most preferably -CR⁵=CR⁶-. It will be understood that when -A- is -CR⁵=CR⁶- the double bond can be cis or trans. Both isomers are part of the invention. Preferably the double bond is trans.

15 R³ preferably represents hydrogen.


 R⁴ preferably represents hydrogen.

 R⁵ preferably represents hydrogen.


 R⁶ preferably represents hydrogen.

Accordingly, examples of particular values for -A-are


20 -E preferably represents a heterocycle selected from:




- 10 -



5 Most preferably -E represents



Further preferred example of particular values for -E is a heterocycle of the formula



10 -A-E can be attached to the 1 or the 2 position of the naphthalene ring. Preferably -A-E is attached to the 2 position of the naphthalene ring.

It will be appreciated that when p is other than zero, then the R¹ substituents can be different. Similarly, when q is

15 other than zero, then the R² substituents can be different.

R¹ is preferably selected from C₁-C₆ alkyl, C₁-C₆ alkoxy halogen, trifluoromethyl.



R² is preferably selected from C₁-C₆ alkyl, C₁-C₆ alkoxy halogen, trifluoromethyl.

- 11 -

When -A-E is attached to the 2 position of the naphthalene ring, p is 1 or 2 it is preferred that one R² group is attached to the 1 position of the naphthalene ring.

5 Preferred compounds are those having one or more or any combination of the following features:

- a) p is 2;
- b) p is 1;
- 10 c) p is 0;
- d) q is 2;
- e) q is 1;
- f) q is 0;
- g) R¹ is selected from C₁-C₆ alkyl, C₁-C₆ alkoxy halogen or trifluoromethyl;
- 15 h) R² is selected from C₁-C₆ alkyl, C₁-C₆ alkoxy halogen or trifluoromethyl;
- i) R² is C₁-C₆ alkoxy, especially methoxy;
- j) -E is a heterocycle selected from:



- k) R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² are each independently selected from C₁-C₆ alkyl, especially methyl, C₁-C₆ alkoxy, especially methoxy, halogen, especially chloro and fluoro, trifluoromethyl, amino, a substituted or unsubstituted phenyl, and a substituted or unsubstituted phenoxy;
- 25 l) -A- is -CR⁵=CR⁶-;


- 12 -

- m) R^5 is hydrogen;
- n) R^6 is hydrogen;
- o) -A- is $-\text{CHR}^3-\text{CHR}^4-$;
- p) R^3 is hydrogen;
- 5 q) wherein R^4 is hydrogen;
- r) -A- is $-\text{C}\equiv\text{C}$;
- s) -A- is $-\text{COO}-$;
- t) -A-E is attached to the 1 position of the naphthalene ring;
- 10 u) -A-E is attached to the 2 position of the naphthalene ring;
- v) -A-E is attached to the 1 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 2 position of the naphthalene ring;
- 15 w) -A-E is attached to the 1 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 3 position of the naphthalene ring;
- x) -A-E is attached to the 1 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 4 position of the naphthalene ring;
- 20 y) -A-E is attached to the 2 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 1 position of the naphthalene ring;
- z) -A-E is attached to the 2 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 3 position of the naphthalene ring; and
- 25 aa) -A-E is attached to the 2 position of the naphthalene ring, p is 2 or 1 and one R^2 is attached to the 4 position of the naphthalene ring;

30


- 13 -

Particularly preferred compounds are of the formula




wherein A, E, R^2 , R^{11} and q are as defined above.

5 More particularly preferred compounds are of the formula




wherein A, R^2 , R^{11} and q are defined above.

Even more particularly preferred compounds are of the
10 formula



wherein R^2 , R^{11} and q are defined above.

Examples of particularly preferred compounds are of the
formula



15

wherein R^2 and R^{11} are defined above.

- 14 -

Particular examples of the compounds of the invention are

4-[2-(2-(1-methoxy)naphthyl)vinyl]pyridine,

4-[2-(2-(1-methoxy)naphthyl)ethyl]pyridine,

5

4-[2-(2-(1-ethoxy)naphthyl)vinyl]pyridine,

4-[2-(2-(1-propyloxy)naphthyl)vinyl]pyridine
hydrochloride,

10

4-[2-(2-(1-ethoxycarbonylmethyl)
oxy)naphthyl)vinyl]pyridine,

4-[2-(2-(1-(methoxyethoxy)naphthyl)vinyl]pyridine,

15

hydrochloride,

4-[2-(2-(1-(cyclopropylmethyloxy)naphthyl)vinyl]pyridine,
hydrochloride,

20

4-[2-(2-(1-propargyloxy)naphthyl)vinyl]pyridine,

4-[2-(2-(1-bromo)naphthyl)vinyl]pyridine,

4-[2-(2-(1-(thiomethyl)naphthyl)vinyl]pyridine,

25

4-[2-(2-(1-chloro)naphthyl)vinyl]pyridine,

4-[2-(2-(1-chloro)naphthyl)ethyl]pyridine,

30

4-[2-(2-(1-cyano)naphthyl)vinyl]pyridine,

4-[2-(2-(1-trifluoromethyl)naphthyl)vinyl]pyridine,

4-[2-(2-(1-nitro)naphthyl)vinyl]pyridine,

- 15 -

4-[2-(2-(3-(methyl)naphthyl)vinyl)pyridine,
4-[2-(2-(3-(chloro)naphthyl)vinyl)pyridine,
5 4-[2-(2-(3-(thiomethyl)naphthyl)vinyl)pyridine,
4-[2-(2-(3-thiomethyl)naphthyl)ethyl]pyridine,
10 4-[2-(2-(1-methoxy)naphthyl)vinyl]pyrimidine,
4-[2-(2-naphthyl)vinyl]pyrimidine,
2-[2-(2-(1-methoxy)naphthyl)vinyl]thiazole,
15 *trans*-3-fluoro-4-[2-(2-naphthyl)vinyl]pyridine,
cis-3-fluoro-4-[2-(2-naphthyl)vinyl]pyridine,
20 4-[2-(2-naphthyl)ethynyl]pyridine, and
4'-pyridyl 1-methoxy-2-naphthoate.

The present invention includes pharmaceutically acceptable
25 salts of the formula (I) compounds. These salts can exist
in conjunction with an acidic or basic portion of the
molecule and can exist as acid addition, primary, secondary,
tertiary, or quaternary ammonium, alkali metal, or alkaline
earth metal salts. Generally, the acid addition salts are
30 prepared by the reaction of an acid with a compound of
formula (I). The alkali metal and alkaline earth metal
salts are generally prepared by the reaction of the
hydroxide form of the desired metal salt with a compound of
formula (I).

- 16 -


Acid addition salts are preferably the pharmaceutically acceptable, non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric, salicylic, o-acetoxybenzoic, or organic sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, or naphthalene-2-sulphonic acid.

In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically-acceptable, acid addition salts, or are useful for identification, characterisation or purification.

Certain compounds of formula I are believed to be novel, and are provided as a further aspect of the invention.

Accordingly, the present invention provides novel compounds of general formula:

2. A compound of the formula:



where p is 0 to 4, q is 0 to 3,

-A- represents a group $-\text{CHR}^3-\text{CHR}^4-$, $-\text{CR}^5=\text{CR}^6-$, $-\text{C}\equiv\text{C}-$, or $-\text{COO}-$,

- 17 -

wherein R³ is hydrogen or hydroxy,

R⁴, R⁵ and R⁶ are each independently hydrogen or C₁-C₆ alkyl, a substituted or unsubstituted phenyl, carboxy(C₁-C₆)alkyl or cyano;

5 -E represents a substituted or unsubstituted heterocycle;

R¹ and R² are each independently selected from C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy, nitro, cyano, C₁-C₆ alkylthio, halogen, trifluoromethyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted benzyl or a group represented by -O-(CH₂)_{m'}-Y, in which Y represents C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, a substituted or unsubstituted phenyl, C₁-C₆ alkoxy, and m' is 0 or 1;

15 or a pharmaceutically acceptable salt or ester thereof, provided that when m' represents 0, Y does not represent C₁-C₆ alkoxy;

other than 2-[2-(2-(1-chloro)naphthyl)vinyl]pyridine,

2-[2-(2-(1-bromo)naphthyl)vinyl]pyridine,

20 naphthylvinylpyridine,

4-[2-(2-naphthyl)vinyl]-2-nitropyridine,

4-[2-(2-naphthyl)acetyl]pyridine,

4-[2-(2-(6-di-(n-butyl)amino)naphthyl)vinyl]pyridine or


4-[2-(2-naphthyl)ethyl]pyridine.

25 The invention also includes a process for preparing a novel compound according to formula (I) or a pharmaceutically acceptable salt or ester thereof.

30 1. The compounds of formula (I), where -A- is -CH=CH-, can be made by the following reactions, which comprise


- 18 -

(a) reacting a compound of formula



5 wherein R^1 , R^2 , p and q are as defined above, with a compound of formula $E-CH_3$, wherein E has the values given above,

(b) reacting a compound of formula




10

wherein R^1 , R^2 , p and q are as defined above, and G is a group of the formula $-CH_2-(PO)-(OR')_2$ or $-CH_2-P(R')_3$, wherein R' is a C_1-C_6 alkyl, with a compound of formula

15

$E-CHO$ wherein E has the values given above, or,

(c) reacting a compound of formula



20

wherein R^1 , R^2 , p , q and E are as defined above, with a suitable reactant such as methanesulphonyl chloride;


The reactions are carried out preferably at a range of

25 temperatures varying from $0^\circ C$ up to reflux. It is also


- 19 -

preferred in process variants (a) and (c) that the reaction is carried out in the presence of a suitable base such as for example sodium acetate in variant (a) and triethylamine in variant (c). It is further preferred that the reaction is
 5 carried out in a suitable organic solvent such as acetic anhydride or dichloromethane;

The intermediates in process variants (a) and (b) are readily available or are synthesized by conventional
 10 methods. The intermediate (Ic) is prepared via anionic condensation of the alkyl naphthyl (IIc) with the aldehyde (IIIc) using conventional methods;



(IIc)




(IIIc)

15

2. The compounds of formula (I), where -A- is $\text{-C}\equiv\text{C-}$, can be made by the following reaction, which comprises

(d) reacting a compound of formula



(Id)

20

wherein p, q, R^1 , and R^2 are as defined above, and L is a suitable leaving group, such as for example an iodo group, with a compound of formula

25 $\text{HC}\equiv\text{C-E}$, wherein -E has the values given above.



- 20 -

The reaction is carried out preferably at a range of temperatures varying from room temperature up to reflux, in the presence of a suitable catalyst, such as for example $(PPh_3)_2PdCl_2$. It is further preferred that the reaction is carried out in the presence of CuI, in a suitable organic solvent such as triethylamine, used also as a base;

The intermediate $HC\equiv C-E$ is synthesized in two steps, using standard procedures, by Palladium catalyst condensation with trimethylsilylacetylene with L-E, wherein L is a leaving group, as defined above, followed by subsequent deprotection using a suitable base such as, for example, K_2CO_3 .

3. The compounds of formula (I), where -A- is $-CH_2-CH_2-$, can be made by the following reaction, which comprises

(e) reducing compounds of formula



wherein p, q, m, R^1 , R^2 and E are as defined above.

The reaction is carried out preferably at a range of temperatures varying from $0^\circ C$ up to room temperature, in

- 21 -


the presence of a suitable catalyst, such as for example PtO_2/C or Pd/C , in a suitable organic solvent such as ethyl acetate;

5 The intermediates (Ie) and (Ie') are as shown in process variants (a), (b), (c) and (d).

4. The compounds of formula (I), where -A- is $-\text{COO}-$, or $-\text{CO}-$, can be made by the following reaction, which comprises

10

(f) condensing a compound of formula



wherein R^1 , R^2 , p and q are as defined above, with a
15 compound of formula $\text{E}'\text{-OH}$, wherein E' is a heterocycle substituted with a hydroxyl group and 1 to 2 times with a group R^4 , wherein R^4 is as defined above.

Please note that when E' is a nitrogen containing
20 heterocycle, it can react through the hydroxyl group to give compounds where -A- is $-\text{COO}-$.

The reaction can be carried out using conventional
methods, such as in the presence of an acyl chloride, such
25 as for example, oxalyl chloride, or in the presence of a coupling agent, such as for example, dicyclohexylcarbodiimide, N,N -carbonyldiimidazole or 2-chloro-1-methylpyridinium iodide. In any instance, the reaction is carried out preferably at a range of
30 temperatures varying from 0°C up to reflux, optionally in the presence of a suitable base, such as for example,

- 22 -


triethylamine, in a suitable organic solvent such as dichloromethane;

The intermediate (If) is readily available or it is
5 synthesized by conventional methods.

5. The compounds of formula (I), where R^2 is
-O-(CH₂)_{m'}-Y, can be made by the following reaction, which
comprises

10

(g) reacting a compound of formula



15 wherein R^1 , R^2 , A, p and E are as defined above, and q' is
independently 0 or 1, with a compound of formula L'-
(CH₂)_{m'}-Y, where m' and Y are as defined above, and L' is a
suitable leaving group, such as for example iodo, bromo or
chloro;

20

The reaction is carried out preferably at a range of
temperatures varying from 0°C up to room temperature,
optionally in the presence of a suitable alkaline base
25 such as for example sodium hydride, in a suitable organic
solvent, such as N,N-dimethylformamide;

The intermediate (Ig) is synthesized as shown in process
variants above.

30

- 23 -

It will be appreciated that all these process variants may be optionally followed by the formation of esters or salts thereof.

5 The present invention further provides the novel starting materials described herein.

 The particular effective amount or dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the
10 case, including the compound administered, the route of administration, the particular condition being treated, and similar considerations. The compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, or intranasal
15 routes. Alternatively, the compound may be administered by continuous infusion. A typical daily dose will contain from about 0.01 mg/kg to about 100 mg/kg of the active compound of this invention. Preferably, daily doses will be about 0.05 mg/kg to about 50 mg/kg, more preferably from about 0.1
20 mg/kg to about 25 mg/kg.

 The activity of compounds according to the invention may be demonstrated in the following test, which involves the electrophysiological characterization of test compounds using HEK293 cells stably expressing human GluR6. The cells
25 may be obtained as described in Hoo, K. H., et al., Receptors Channels 1994, 2, 327-337.

 In the test, cells are dissociated by trituration and plated out onto poly-L-lysine coated (10 μ g/ml) glass
30 coverslips. Whole-cell voltage clamp recordings (V_h = -70mV) are made using the tight seal whole cell configuration of the patch-clamp technique (Hamill et al., (1981) Pflügers Arch., 391: 85-100). Glass fragments of coverslips with adherent cells are placed in a perfusion

- 24 -

chamber, pre-incubated with 250 μ g/ml concanavalin A to remove agonist-induced desensitization, and rinsed with buffer of composition: 138mM NaCl, 5mM CaCl₂, 5mM KCl, 1mM MgCl₂, 10mM HEPES and 10mM glucose, pH of 7.5 with NaOH (osmolality 315 mosm/kg). The recording pipette solutions contain 140mM CsCl, 1mM MgCl₂, 14mM HEPES (N-[2-hydroxyethyl]-piperazin-N'-[2-ethanesulfonic acid]) and 15mM BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N',-tetraacetic acid), pH of 7.2 with CsOH (osmolality 295 mosm/kg). Experiments were performed at ambient temperature (20-22 °C) and recorded on either a List EPC-7 or an Axopatch ID amplifier.

Cells were superfused with solution containing agonist (1mM kainate) in buffer and steady state current values obtained. Agonist in the presence of compound was then applied and the reduction in the inward current from control kainate-induced current measured. The reduction in current produced by the compound was assessed at steady state. Recovery of control currents elicited by kainate (1 μ M) was established by repeat application of kainate to the cells via the external solution. The compound tested were evaluated for use-dependency. The recovery from compound inhibition of kainate-induced current was dependent upon the rate of repeat kainate application following antagonist inhibition of currents. In addition, outward currents measured by voltage-clamping at positive potentials (+70mV) were not inhibited by the compounds whereas inward currents were.

All of the compounds exemplified herein have been found to show activity in this test at a concentration of 30 micromolar or lower.

The compounds of the present invention are preferably formulated prior to administration. Therefore, another

- 25 -

aspect of the present invention is a pharmaceutical formulation comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.. The present

5 pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients. In making the formulations of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in

10 the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders,

15 lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example, up to 10% by weight of active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

20 Some examples of suitable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl

25 cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. Formulations of the

30 invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

- 26 -

The formulations are preferably formulated in a unit dosage form, each dosage containing from about 5 mg to about 500 mg, more preferably about 25 mg to about 300 mg of the active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutically acceptable carrier.


The following examples are illustrative of compounds for use in the manufacture of a medicament for the treatment of a condition indicating treatment with a GluR6 antagonist.

Materials and Methods. All solvents and reagents were purchased from commercial sources and used as received, unless otherwise indicated. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl prior to use; N-Dimethylformamide (DMF) was dried over 4 Å molecular sieves; Triethylamine (Et₃N) was distilled from calcium hydride. The reactions done with these solvents were performed under a positive pressure of argon. ¹H-NMR and ¹³C-NMR data were recorded on a Bruker AC-200P and a Varian Unity 300. IR spectra were obtained on Nicolet 510 P-FT and a Perkin Elmer 883 (KBr). Melting points were determined on a Electrothermal IA6304 apparatus and are not corrected. MS spectra were recorded on a Hewlett-Packard 5988A (70 eV) utilizing chemical ionization (CI). Analytical TLC was performed on Merck TLC glass plates precoated with F₂₅₄ silica gel 60 (UV, 254 nm and Iodine). Chromatographic separations were performed by using 230-400 mesh silica gel (Merck).

Example 1

Synthesis of 4-[2-(2-(1-methoxy)naphthyl)vinyl]pyridine (3)

- 27 -




To a suspension of NaH (95%, 590 mg., 23.38 mmol.) in 20 ml of DMF is added, portionwise, the acid **1** (2 g., 10.63 mmol.) at 0°C . The resulting mixture is stirred at this temperature during 30 m. and, then, 1.45 ml. (23.38 mmol.) of methyl iodide are added. The reaction is maintained for 2h., quenched with H_2O and extracted with CH_2Cl_2 . The organic phase is dried over Na_2SO_4 , filtered and evaporated to dryness. It is obtained a pale yellow residue which is solved in 10 ml of THF and treated, at 0°C , with 27.8 ml (27.8 mmol.) of a 1M solution of Dibal-H in THF. After the addition, the reaction is stirred at room temperature overnight and quenched, at 0°C , with a saturated solution of NH_4Cl . Then, it is extracted with CH_2Cl_2 and the organic phase washed with H_2O , dried over Na_2SO_4 and evaporated to dryness. The crude product is purified by flash chromatography using hexane/EtOAc (1:1) as eluent, yielding a white solid. This solid is solved in 30 ml. of CH_2Cl_2 and treated with 2.45 g. (11.2 mmol.) of PCC. The mixture is stirred at room temperature for 1 h. Then, it is filtered off through celite and the celite washed three times with CH_2Cl_2 . The filtrate is evaporated to dryness and the residue is purified by flash chromatography using hexane/EtOAc (9:1) as eluent. It was obtained **2** (1.3 g., 67%) as a white solid. To a suspension of 550 mg. (2.95 mmol.) of **2** and 485 mg. (5.91 mmol.) of NaOAc in 5 ml. of Ac_2O are added 280 mg. (2.95 mmol.) of 4-Picoline and the mixture heated at reflux. After 4 h. it is added another

- 28 -

equivalent of 4-Picoline and the reaction heated overnight. Once the reaction is cooled to room temperature, it is treated with a saturated solution of NaHCO_3 until $\text{pH} = 8$. Then, the aqueous phase is extracted twice with CH_2Cl_2 and the organic phase is dried over Na_2SO_4 , filtered off and evaporated to dryness. The black residue is purified by flash chromatography using hexane/EtOAc (1:1) as eluent, yielding **3** as a pale brown solid. MS (CI): 262 ($\text{M}^+ + 1$, 100).

10 **Example 2**

Synthesis of 4-[2-(2-(1-methoxy)naphthyl)ethyl]pyridine] (4**)**




15 A mixture of 40 mg. (0.153 mmol.) of **3** and 14 mg. (0.062 mmol.) of PtO_2 in 5 ml. of EtOAc is treated with H_2 (balloon pressure) during 4 h. at room temperature. Then, the reaction is filtered off through celite. The celite is washed twice with EtOAc and the filtrate is evaporated to dryness. The residue is purified by flash chromatography using EtOAc as eluent, affording 33 mg. (82%) of **4** as a transparent oil. The oil is solved in Et_2O and treated with 1 ml. of a saturated solution of HCl in Et_2O to isolate the hydrochloride of **4** as a white solid. MS (CI): 264 ($\text{M}^+ + 1$, 100).

25 **Example 3**

General procedure for the synthesis of the ether derivatives

- 29 -



A solution of 1.08 g. (4.1 mmol.) of **3** and 840 mg. (10 mmol.) of sodium thioethoxide in 10 ml. of DMF is heated at 100° C over 2 h. Then, the reaction mixture is cooled down to 0° C and treated with a 2M solution of HCl. The generated precipitate is filtered off and washed with H₂O and Et₂O, yielding the phenol **5** as a pale brown solid in a 83% yield. A solution of the phenol **5** (0.7 mmol.) in 6 ml. of DMF is treated, at 0° C, with NaH (2 equiv.). The reaction mixture is stirred at room temperature for 30 m. and, then, the corresponding alkylating agent (1.1 equiv.) is added. The mixture is stirred during 20 h., quenched with a saturated solution of NH₄Cl and extracted with CH₂Cl₂. The organic phase is washed with H₂O, dried over Na₂SO₄ and evaporated to dryness. The residue is purified by flash chromatography using EtOAc as eluent, yielding the desired ether **6**. The derivatives which are not solid are treated with a saturated solution of HCl in Et₂O in order to generate the corresponding hydrochloride, which is solid in all cases.

4-[2-(2-(1-ethoxy)naphthyl)vinyl]pyridine (**6a**). MS (CI): 276 (M⁺+1, 100).

- 30 -

4-[2-(2-(1-propyloxy)naphthyl)vinyl]pyridine, hydrochloride
(6b). Mp: 190-191° C.

4-[2-(2-(1-(ethoxycarbonylmethyl)oxy)naphthyl)vinyl]pyridine
5 (6c). MS (CI): 334 ($M^+ + 1$, 100).

4-[2-(2-(1-(methoxyethoxy)naphthyl)vinyl]pyridine,
hydrochloride (6d). MS (CI): 306 ($M^+ + 1$, 100).


10 4-[2-(2-(1-(cyclopropylmethyloxy)naphthyl)vinyl]pyridine,
hydrochloride (6e). MS (CI): 302 ($M^+ + 1$, 100).

4-[2-(2-(1-propargyloxy)naphthyl)vinyl]pyridine (6f). MS
(CI): 286 ($M^+ + 1$, 100).

15

Example 4

Synthesis of 4-[2-(2-(1-bromo)naphthyl)vinyl]pyridine (9)



20


A solution of 11.1 g. (45.23 mmol.) of 1-bromo-2-methylnaphthalene (7), 9.66 g. (54.27 mmol.) of N-Bromosuccinimide (NBS) and 0.9 g. (5.43 mmol.) of AIBN in 50 ml. of dry CCl₄ is refluxed, under argon atmosphere, for 6
25 h. Then, the reaction is cooled down to room temperature and filtered off. The filtrate is evaporated to dryness and the residue is purified by flash chromatography using hexane as eluent, yielding 9.8 g. (72%) of the desired benzyl bromide as a white solid. A solution of 8 g. (26.66 mmol.) of this
30 bromide and collidine (3.8 ml., 28 mmol.) in 50 ml. of dry

- 31 -

DMSO is stirred at room temperature during 5 days. Then, it is added H₂O and the mixture extracted twice with Et₂O. The organic phase is washed with H₂O, dried over Na₂SO₄ and evaporated to dryness. The crude is purified by flash chromatography using toluene as eluent, affording 3 g. (48%) of the aldehyde **8** as a white solid. A suspension of 2 g. (8.51 mmol.) of **8** and 1.4 g. (17 mmol.) of NaOAc in 15 ml. of Ac₂O is treated with 0.83 ml. (8.51 mmol.) of 4-picoline and the mixture heated at reflux over 2 h. After that time, it is added another equivalent of 4-picoline and the reaction maintained overnight at reflux. The reaction is cooled down until 0° C and neutralised with a saturated solution of NaHCO₃. The aqueous phase is extracted with CH₂Cl₂ and the organic phase is washed with H₂O, dried over Na₂SO₄ and evaporated at vacuum. The crude is purified by flash chromatography using CH₂Cl₂/EtOAc (8:2) as eluent. The desired product **9** was obtained as a pale brown solid. MS (CI): 312 (M⁺+3, 100), 310 (M⁺+1, 81).

20 Example 5

Synthesis of the derivatives **10**



25 A solution of 0.5 mmol. of **9** in 3 ml. of THF is treated, at -78° C, with a 1.6M solution of *n*-BuLi in hexane (1.1 equiv.) After 30 m., it is added the corresponding electrophile (2 equiv.) and the reaction mixture slowly warmed-up until room temperature. Then, it is quenched with

- 32 -


a saturated solution of NH_4Cl and extracted with CH_2Cl_2 . The organic phase is dried over Na_2SO_4 , filtered off and evaporated to dryness. The residue is purified by flash chromatography using $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (8:2) as eluent and
5 yielding the desired product **10** as a white solid.

4-[2-(2-(1-(thiomethyl)naphthyl)vinyl)pyridine (10a). MS (CI): 278 ($\text{M}^+ + 1$, 100).

10 **4-[2-(2-(1-chloro)naphthyl)vinyl)pyridine (10b).** MS (CI): 268 ($\text{M}^+ + 3$, 33), 266 ($\text{M}^+ + 1$, 100), 232 ($\text{M}^+ + 2 - \text{Cl}$, 12).

Example 6

15 Synthesis of 4-[2-(2-(1-chloro)naphthyl)ethyl]pyridine (**11**)




A mixture of 50 mg. (0.188 mmol.) of **10b** and 15 mg. (0.063 mmol.) of PtO_2 in 5 ml. of EtOAc is treated with H_2 (balloon pressure) during 5 h. at room temperature. Then, the reaction is filtered off through celite. The celite is washed twice with EtOAc and the filtrate is evaporated to dryness. The residue is purified by flash chromatography
20 using EtOAc as eluent, yielding **11** as a pale brown solid. MS (CI): 270 ($\text{M}^+ + 3$, 37), 268 ($\text{M}^+ + 1$, 100), 234 (9).

Example 7

Synthesis of 4-[2-(2-(1-cyano)naphthyl)vinyl]pyridine (**12**)


- 33 -



A suspension of 80 mg. (0.26 mmol.) of **9**, 18 mg. (0.01 mmol.) of $(\text{PPh}_3)_4\text{Pd}$ and 22 mg. (0.19 mmol.) of $\text{Zn}(\text{CN})_2$ in 1 ml. DMF is heated in a sealed tube, at 120° C, for a week. Then, the reaction mixture is cooled down to room temperature, poured into a 5% solution of NaOH and extracted with CH_2Cl_2 . The organic phase is dried over Na_2SO_4 , filtered off and evaporated at vacuum. The crude is purified by flash chromatography using EtOAc as eluent, yielding **12** as a pale brown solid. MS (CI): 257 ($\text{M}^+ + 1$, 100).

Example 8

Synthesis of 4-[2-(2-(1-trifluoromethyl)naphthyl)vinyl]pyridine (**16**)



A solution of 5 g. (31.6 mmol.) of **13** in 30 ml of CH_2Cl_2 is treated, at room temperature, with Iodo-bis-pyridinium tetrafluoroborate (1.1 equiv.) and

- 34 -

tetrafluoroboric acid (1 equiv.). After 1.5 h., the reaction is poured into H₂O and extracted with more CH₂Cl₂. The organic phase is dried over Na₂SO₄, filtered off and evaporated to dryness. The crude mixture is purified by

5 flash chromatography using CH₂Cl₂/MeOH (97:3) as eluent, affording the desired iodo-derivative as a brown solid (2.7 g., 30%). A solution of 2 g. (7.05 mmol.) of the iodo-derivative in 20 ml. of CH₂Cl₂ is treated with 2.27 g. (10.56 mmol.) of PCC at room temperature. After 1 h., the

10 reaction mixture is filtered off through celite. The celite is washed three times with CH₂Cl₂ and the combined organic extracts are evaporated at vacuum. The residue is purified by flash chromatography using toluene as eluent, yielding 1.7 g. (86%) of **14** as a pale yellow solid. A suspension of

15 200 mg. (0.709 mmol.) of **14**, 80 mg. (0.420 mmol.) of CuI and 181 μ L (1.42 mmol.) of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate in 4 ml. of DMF is heated, at 100°C, for 7 h. in a sealed tube. Then, the reaction mixture is cooled down to room temperature, poured into H₂O and

20 extracted with Et₂O. The organic phase is dried over Na₂SO₄, filtered off and evaporated to vacuum. The crude mixture is purified by flash chromatography using hexane/toluene (8:2) as eluent, affording 114 mg. (72%) of **15** as a transparent oil. To a suspension of 95 mg. (0.424 mmol.) of **15** in 2 ml.

25 of Ac₂O are added 45 μ L (0.424 mmol.) of 4-picoline and the reaction mixture heated, under argon atmosphere, at reflux for 4 h. Another equivalent of 4-picoline is added and the reaction maintained along 16 h. Then, the mixture is cooled down to 0°C, neutralised with a saturated solution of


30 NaHCO₃ and extracted with CH₂Cl₂. The organic phase is dried over Na₂SO₄, filtered off and evaporated to dryness. The residue is purified by flash chromatography using

- 35 -

hexane/toluene (6:4) as eluent. It is obtained **16** as a brown solid. MS (CI): 300 ($M^+ + 1$, 100), 246 (6), 178 (7).

Example 9

5 Synthesis of 4-[2-(2-(1-nitro)naphthyl)vinyl]pyridine (**19**)



10 A solution of 1.6 ml. (11.2 mmol.) of di-isopropylamine in 10 ml. of THF is treated, at 0° C, with 6.8 ml. (11 mmol.) of a 1.6M solution of n-BuLi in hexane. After 45 m., this mixture is added, "via cannula", to a solution of 2 g. (10.7 mmol.) of **17** in 20 ml. of THF, at -78° C. The reaction

15 mixture become deep green. One hour later, it is added 4-pycolylcarbaldehyde (1.1 ml., 11.2 mmol.) and the reaction is slowly warmed-up until room temperature. Then, it is quenched with a saturated solution of NH₄Cl, poured into H₂O and extracted with CH₂Cl₂. The organic phase is dried over

20 Na₂SO₄, filtered off and evaporated to dryness. The crude is purified by flash chromatography using CH₂Cl₂/EtOAc (1:1) as eluent, affording 1.5 g. (48%) of **18** as a white solid. A solution of 500 mg. (1.7 mmol.) of **18** and 1.2 ml. (8.5 mmol.) of Et₃N in 5 ml. of CHCl₃ is treated with 0.2 ml.


25 (2.5 mmol.) of mesyl chloride and the mixture heated at reflux for 24 h. Once the reaction gets room temperature, it is poured into a saturated solution of NaHCO₃ and extracted with CH₂Cl₂. The organic phase is dried over Na₂SO₄, filtered off and evaporated at vacuum. The residue is purified by

- 36 -

flash chromatography using EtOAc as eluent, yielding **19** as a pale brown solid. MS (CI): 277 ($M^+ + 1$, 100), 245 (12).

Example 10

5 Synthesis of the derivatives 22



- 10 A solution of 1.8 ml. (14 mmol.) of trimethylethylenediamine in 35 ml. of THF is treated, at -30°C, with 8.4 ml. (13.4 mmol.) of a 1.6M solution of *n*-BuLi in hexane. After 15 m., it is added a solution of 2 g. (12.8 mmol.) of 2-naphthaldehyde (**20**) in 5 ml. of THF and
- 15 the reaction mixture maintained at -30°C for 15 m. Then, it is treated with 24 ml. (38.4 mmol.) of a 1.6M solution of *n*-BuLi in hexane and the temperature maintained along 3 h. After that time, a solution of the corresponding electrophile (5 equiv.) in THF is added and the reaction is
- 20 slowly warmed-up to room temperature along 2 h. Finally, the reaction is poured into a 10% solution of HCl and extracted with Et₂O. The organic phase is washed with H₂O, dried over Na₂SO₄, filtered off and evaporated to dryness. The residue is purified by flash chromatography using hexane/EtOAc
- 25 (9.5:0.5) as eluent. It is obtained the desired aldehyde **21** as a solid with yields between 60-15%. A suspension of the corresponding aldehyde **21** (4 mmol.) and NaOAc (2 equiv.) in 10 ml. of Ac₂O is treated with 4-pycoline (1 equiv.) and the

- 37 -

reaction heated, under argon atmosphere, at reflux for 4 h., when it is added another equivalent of 4-pycoline. Then, the mixture is maintained at reflux for 20 h. Once the reaction gets room temperature, it is poured into a saturated
5 solution of NaHCO_3 and extracted with CH_2Cl_2 . The aqueous phase is washed with CH_2Cl_2 and the combined organic extracts are dried over Na_2SO_4 , filtered off and evaporated to dryness. The residue is purified by flash chromatography using hexane/EtOAc (1:1) as eluent, affording **22** as a solid.

10


4-[2-(2-(3-(methyl)naphthyl)vinyl)pyridine (**22a**). MS (CI): 246 ($\text{M}^+ + 1$, 100), 178 (5).

4-[2-(2-(3-(chloro)naphthyl)vinyl)pyridine (**22b**). MS (CI):
15 268 ($\text{M}^+ + 3$, 46), 266 ($\text{M}^+ + 1$, 100).

4-[2-(2-(3-(thiomethyl)naphthyl)vinyl)pyridine (**22c**). MS (CI): 278 ($\text{M}^+ + 1$, 100).

20 **Example 11**

Synthesis of 4-[2-(2-(3-thiomethyl)naphthyl)ethyl]pyridine (**23**)




25

A mixture of 30 mg. (0.11 mmol.) of **22c** and 15 mg. (0.063 mmol.) of PtO_2 in 5 ml. of EtOAc is treated with H_2 (balloon pressure) during 20 h. at room temperature. Then, the reaction is filtered off through celite. The celite is

- 38 -

washed twice with EtOAc and the filtrate is evaporated to dryness. The residue is purified by flash chromatography using EtOAc as eluent, affording **23** as a white solid. IR (KBr): 2925, 1594, 1416, 874, 812, 747 cm^{-1} .

5

Example 12Synthesis of the derivatives **24**

10

A suspension of 1.5 mmol. of the corresponding aldehyde (**2**, **20**) and NaOAc (2 equiv.) in 3 ml. of Ac_2O is treated with 4-methylpyrimidine (1 equiv.) and the reaction heated, under argon atmosphere, at reflux for 20 h. Once the reaction gets room temperature, it is poured into a saturated solution of NaHCO_3 and extracted with CH_2Cl_2 . The aqueous phase is washed with CH_2Cl_2 and the combined organic extracts are dried over Na_2SO_4 , filtered off and evaporated at vacuum. The crude is purified by flash chromatography using $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) as eluent, affording **24** as a solid.

20


4-[2-(2-(1-methoxy)naphthyl)vinyl]pyrimidine (24a). MS (CI): 263 ($\text{M}^+ + 1$, 100).

25

4-[2-(2-naphthyl)vinyl]pyrimidine (24b). MS (CI): 233 ($\text{M}^+ + 1$, 100).

Example 13Synthesis of 2-[2-(2-(1-methoxy)naphthyl)vinyl]thiazole (**27**)

- 39 -




To a suspension of 1.9 g. (10 mmol.) of **25** (obtained
 5 from **1** after steps 1 and 2) and 4 g. (15 mmol.) of PPh_3 in
 15 ml. of DMF is added, portionwise, 2.6 g. (14.5 mmol.) of
 NBS. The mixture is heated at 50°C for 15 m. Then, the
 reaction is cooled down to room temperature and quenched
 with 3.5 ml. of methanol. After 10 m., the reaction mixture
 10 is poured into H_2O and extracted with Et_2O . The organic
 phase is subsequently washed with a saturated solution of
 Na_2CO_3 , H_2O and brine. Then, it is dried over Na_2SO_4 ,
 filtered off and evaporated at vacuum. The residue is
 purified by flash chromatography using hexane/ EtOAc (4:1) as
 15 eluent, yielding the desired brominated derivative as a
 white solid (1.25 g., 50%). A suspension of 1 g. (4 mmol.)
 of the brominated derivative in 1 ml. of $\text{P}(\text{OEt})_3$ is heated
 at 120°C , under argon atmosphere, for 2 days. Once the
 reaction gets room temperature, it is added H_2O and the
 20 mixture extracted with CH_2Cl_2 . The organic phase is dried
 over Na_2SO_4 , filtered off and evaporated to dryness. The
 residue is purified by flash chromatography using
 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) as eluent, yielding 900 mg. (75%) of **26**
 as a white solid. A suspension of 77 mg. (0.25 mmol.) of **26**
 25 in 1 ml. of DMF is treated, at 0°C , with a solution of 55
 mg (0.27 mmol.) of KHMDS in 1 ml. of DMF. The reaction
 mixture is maintained at this temperature for 20 m. and,
 then, a solution of 28 mg. (0.25 mmol.) of 2-
 thiazolcarboxaldehyde in 1 ml. of DMF is added. The
 30 reaction is warmed-up to room temperature and maintained at

- 40 -

this temperature during 1 h. After that, it is quenched with a saturated solution of NH_4Cl , poured into H_2O and extracted with CH_2Cl_2 . The organic phase is dried over Na_2SO_4 , filtered off and evaporated to dryness. The crude is purified by
5 flash chromatography using $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) as eluent, affording 20 mg. (30%) of **27** as a pale yellow oil. In order to get a solid, **27** is solved in 1 ml. of Et_2O and treated with 1 ml. of a saturated solution of HCl in Et_2O . The formed hydrochloride of **27** is filtrated and washed with
10 Et_2O , yielding pure **27**, as a pale yellow solid. MS (CI): 268 ($\text{M}^+ + 1$, 100).

Example 14

Synthesis of *cis* and *trans* 3-Fluoro-4-[2-(2-naphthyl)vinyl]pyridines **30**
15



A suspension of 0.46 g. (1.15 mmol.) of **28** (obtained
20 from 2-(bromomethyl)naphthalene by treatment with PPh_3) in 4 ml. of THF is treated, at 0°C , with 0.75 ml. (1.21 mmol.) of a 1.6M solution of $n\text{-BuLi}$ in hexane. The reaction is maintained at this temperature for 1 h. and, then, a solution of 0.14 g. (1.1 mmol.) of **29** (obtained from 3-
25 fluoropyridine in a single step, applying a standard

- 41 -


procedure) in 2 ml. of THF is added. After the addition, the mixture is warmed-up to room temperature and maintained along 3 h. Then, the reaction is quenched with a saturated solution of NH_4Cl , poured into a saturated solution of NaHCO_3 and extracted with CH_2Cl_2 . The organic extracts are dried over Na_2SO_4 , filtered off and evaporated at vacuum. The crude is purified by flash chromatography using CH_2Cl_2 /hexane (4:1) as eluent, affording 70 mg. of **30a** as a pale yellow oil and 50 mg. of **30b** as a pale yellow solid, in a combined yield of 72%. The isomer **30a** was transformed into the hydrochloride derivative in order to get a solid.

Trans-3-Fluoro-4-[2-(2-naphthyl)vinyl]pyridine Hydrochloride (30a). MS (CI): 250 ($\text{M}^+ + 1$, 100).

Cis-3-Fluoro-4-[2-(2-naphthyl)vinyl]pyridine (30b). MS (CI): 250 ($\text{M}^+ + 1$, 100).

Example 15

Synthesis of 4-[2-(2-naphthyl)ethyl]pyridine (**34**)



i) A suspension of 90 mg. (0.87 mmol.) of **31** (obtained from 4-bromopyridine in two steps, using standard procedures, by


- 42 -

Palladium catalyst condensation with trimethylsilylacetylene and subsequent deprotection with K_2CO_3 , 220 mg. (0.87 mmol.) of **32**, 17 mg. (0.087 mmol.) of CuI and 31 mg. (0.043 mmol.) of $(PPh_3)_2PdCl_2$ in 5 ml. of Et_3N is stirred, under
5 argon atmosphere, at room temperature for 4 h. Then, the reaction is evaporated to dryness and the crude mixture is treated with CH_2Cl_2 and H_2O . The organic phase is dried over Na_2SO_4 , filtered off and evaporated at vacuum. The residue is purified by flash chromatography using hexane/ $EtOAc$ (7:1)
10 as eluent, affording **33** as a brown solid. MS (CI): 230 (M^{++1} , 93), 229 (M^+ , 100), 228 (M^{+-1} , 41), 227 (M^{+-2} , 77), 230 (M^{+-3} , 87).

ii) A mixture of 45 mg. (0.20 mmol.) of **33** and 5 mg. (0.02 mmol.) of PtO_2 in 2 ml. of $EtOAc$ is treated with H_2 (balloon pressure) during 5 h. at room temperature. Then, the reaction is filtered off through celite. The celite is washed twice with $EtOAc$ and the combined organic extracts evaporated to dryness. The residue is purified by flash
20 chromatography using hexane/ $EtOAc$ (1:1) as eluent, yielding **34** as a white solid. MS (CI): 235 (M^{++2} , 66), 234 (M^{++1} , 86), 233 (M^+ , 14), 232 (M^{+-1} , 100), 231 (M^{+-2} , 77).

Example 16

25 Synthesis of the derivative 36.



A solution of 150 mg. (0.74 mmol.) of **35** (obtained from
30 **1** in two steps) in 5 ml. of CH_2Cl_2 is treated with 0.4 ml.

- 43 -

(0.82 mmol.) of a 2M solution of oxalyl chloride in CH_2Cl_2 and heated at reflux for 1 h. Once the reaction mixture gets room temperature, it is treated subsequently with 0.22 ml. (1.48 mmol.) of Et_3N and 77 mg. (0.82 mmol.) of 4-
5 hydroxypyridine. The mixture is stirred during 20 h., quenched with a saturated solution of NH_4Cl and poured into H_2O . It is extracted with more CH_2Cl_2 and the organic extracts are dried over Na_2SO_4 , filtered off and evaporated to dryness. The residue is purified by flash chromatography
10 using EtOAc as eluent, affording **36**, as a white solid.

4'-Pyridyl 1-methoxy-2-naphthoate (**36**). MS (CI): 280 ($\text{M}^+ + 1$, 100), 202 (5).

- 44 -

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

5	<hr/>	
		Quantity (mg/capsule)
	<hr/>	
10	Active Ingredient	250
	Starch, dried	200
	Magnesium stearate	<u>10</u>
15	Total	460 mg
	<hr/>	

The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.

- 45 -

Formulation 2

Tablets each containing 60 mg of active ingredient are made
as follows:

	Active Ingredient	60 mg
	Starch	45 mg
10	Microcrystalline cellulose	35 mg
	Polyvinylpyrrolidone	4 mg
	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
	Talc	<u>1 mg</u>
15	Total	150 mg

The active ingredient, starch, and cellulose are passed
through a No. 45 mesh U.S. sieve and mixed thoroughly. The
solution of polyvinylpyrrolidone is mixed with the resultant
powders which are then passed through a No. 14 mesh U.S.
sieve. The granules so produced are dried at 50°C and
passed through a No. 18 mesh U.S. sieve. The sodium
carboxymethyl starch, magnesium stearate, and talc,
previously passed through a No. 60 mesh U.S. sieve, are then
added to the granules which, after mixing, are compressed on
a tablet machine to yield tablets each weighing 150 mg.


The following Examples illustrate the invention. In
the Examples, Et₂O signifies diethylether, AcOEt signifies
ethyl acetate, MeOH signifies methanol, THF signifies
tetrahydrofuran, DMF signifies dimethylformamide, and Jones
Reagent signifies a solution of 1.0g of Na₂Cr₂O₇·2H₂O and
1.34 g of sulfuric acid in H₂O (total volume 5 ml).

- 46 -

CLAIMS

1. Use of a compound of the formula:

5



where p is 0 to 4, q is 0 to 3,

-A- represents a group $-\text{CHR}^3-\text{CHR}^4-$, $-\text{CR}^5=\text{CR}^6-$, $-\text{C}\equiv\text{C}$, or
10 $-\text{COO}-$,

wherein R^3 is hydrogen or hydroxy,


R^4 , R^5 and R^6 are each independently hydrogen or C_1-C_6
alkyl, a substituted or unsubstituted phenyl, carboxy(C_1-
 C_6)alkyl or cyano;

15 -E represents a substituted or unsubstituted
heterocycle;

R^1 and R^2 are each independently selected from C_1-C_6
alkyl, hydroxy, C_1-C_6 alkoxy, nitro, cyano, C_1-C_6 alkylthio,
halogen, trifluoromethyl, a substituted or unsubstituted
20 phenyl, a substituted or unsubstituted benzyl or a group
represented by $-\text{O}-(\text{CH}_2)_{m'}-\text{Y}$, in which Y represents C_3-C_6
cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, a substituted or
unsubstituted phenyl, C_1-C_6 alkoxy, and m' is 0 or 1;
or a pharmaceutically acceptable salt or ester thereof,
25 provided that when m' represents 0, Y represents C_3-C_6
cycloalkyl or a substituted or unsubstituted phenyl;
for the manufacture of a medicament for the treatment of a
condition indicating treatment with a GluR6 antagonist.

- 47 -

2. Use as claimed in Claim 1, wherein p is 2.
3. Use as claimed in Claim 1, wherein p is 1.
4. Use as claimed in Claim 1, wherein p is 0.
5. Use as claimed in any one of Claims 1 to 4, wherein q is 2.
6. Use as claimed in any one of Claims 1 to 4, wherein q is 1.
7. Use as claimed in any one of Claims 1 to 4, wherein q is 0.
- 10 8. Use as claimed in any one of Claims 1 to 7, wherein R¹ is selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen or trifluoromethyl.
9. Use as claimed in any one of Claims 1 to 7, wherein R² is selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen or trifluoromethyl.
- 15 10. Use as claimed in any one of Claims 1 to 8 wherein R² is C₁-C₆ alkoxy.
11. Use as claimed in any one of Claims 1 to 8 wherein R² is methoxy.
- 20 12. Use as claimed in any one of Claims 1 to 11, wherein -E is a heterocycle selected from:



13. Use as claimed in any one of Claims 1 to 11, wherein R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹ and R³² are each independently selected from C₁-C₆ alkyl, especially methyl, C₁-C₆ alkoxy, especially methoxy,


- 48 -

halogen, especially chloro and fluoro, trifluoromethyl, amino, a substituted or unsubstituted phenyl, and a substituted or unsubstituted phenoxy.

14. Use as claimed in any one of Claims 1 to 13, wherein
5 -A- is $-CR^5=CR^6-$.
15. Use as claimed in any one of Claims 1 to 14, wherein R^5 is hydrogen.
16. Use as claimed in any one of Claims 1 to 15, wherein R^6 is hydrogen.
- 10 17. Use as claimed in any one of Claims 1 to 13, wherein
 -A- is $-CHR^3-CHR^4-$.
18. Use as claimed in any one of Claims 1 to 13 and 17 wherein R^3 is hydrogen.
19. Use as claimed in any one of Claims 1 to 13, 17 and 18
15 wherein R^4 is hydrogen.
20. Use as claimed in any one of Claims 1 to 13, wherein
 -A- is $-C\equiv C-$.
21. Use as claimed in any one of Claims 1 to 13, wherein
 -A- is $-COO-$.
- 20 22. Use as claimed in any one of Claims 1 to 21, wherein
 -A-E is attached to the 1 position of the naphthalene ring.
23. Use as claimed in any one of Claims 1 to 21, wherein
 -A-E is attached to the 2 position of the naphthalene
25 ring.
24. Use as claimed in any one of Claims 1 to 21, wherein
 -A-E is attached to the 1 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 2 position of the naphthalene ring.
- 30 25. Use as claimed in any one of Claims 1 to 21, wherein
 -A-E is attached to the 1 position of the naphthalene ring, p is 2 or 1 and one R^2 group is attached to the 3 position of the naphthalene ring.


- 49 -

26. Use as claimed in any one of Claims 1 to 21, wherein
-A-E is attached to the 1 position of the naphthalene
ring, p is 2 or 1 and one R^2 group is attached to the 4
position of the naphthalene ring.
- 5 27. Use as claimed in any one of Claims 1 to 21, wherein
-A-E is attached to the 2 position of the naphthalene
ring, p is 2 or 1 and one R^2 group is attached to the 1
position of the naphthalene ring.
28. Use as claimed in any one of Claims 1 to 21, wherein
10 -A-E is attached to the 2 position of the naphthalene
ring, p is 2 or 1 and one R^2 group is attached to the 3
position of the naphthalene ring.
29. Use as claimed in any one of Claims 1 to 21, wherein
-A-E is attached to the 2 position of the naphthalene
15 ring, p is 2 or 1 and one R^2 is attached to the 4
position of the naphthalene ring.
30. Use of a compound of the formula



20 wherein A, E, R^2 , R^{11} and q are as defined in any one of
the preceding claims.


31. Use of a compound of the formula



wherein A, R^2 , R^{11} and q are as defined in any one of the
preceding claims.


- 50 -

32. Use of a compound of the formula



wherein R^2 , R^{11} and q are as defined in anyone of the preceding claims.

5 33. Use of a compound of the formula



wherein R^2 is as defined in anyone of the preceding claims.


34. Use as claimed in Claim 28, wherein R^2 is C_1 - C_6 alkoxy.

10 35. Use as claimed in Claim 29, wherein R^2 is methoxy.

36. Use of a compound according to any of the preceding claims, wherein the condition indicating treatment with a GluR6 antagonist is epilepsy.

37. Any compound of formula I as defined in Claim 1 that is
15 novel.

38. A compound of the formula:



where p is 0 to 4, q is 0 to 3,

20

-A- represents a group $-CHR^3-CHR^4-$, $-CR^5=CR^6-$, $-C\equiv C$, or

- 51 -

-COO-,

wherein R³ is hydrogen or hydroxy,

R⁴, R⁵ and R⁶ are each independently hydrogen or C₁-C₆ alkyl, a substituted or unsubstituted phenyl, carboxy(C₁-C₆)alkyl or cyano;

-E represents a substituted or unsubstituted heterocycle;

R¹ and R² are each independently selected from C₁-C₆ alkyl, hydroxy, C₁-C₆ alkoxy, nitro, cyano, C₁-C₆ alkylthio, halogen, trifluoromethyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted benzyl or a group represented by -O-(CH₂)_{m'}-Y, in which Y represents C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, a substituted or unsubstituted phenyl, C₁-C₆ alkoxy, and m' is 0 or 1;

or a pharmaceutically acceptable salt or ester thereof, provided that when m' represents 0, Y does not represent C₁-C₆ alkoxy;

other than 2-[2-(2-(1-chloro)naphthyl)vinyl]pyridine,

2-[2-(2-(1-bromo)naphthyl)vinyl]pyridine,

naphthylvinylpyridine,

4-[2-(2-naphthyl)vinyl]-2-nitropyridine,

4-[2-(2-naphthyl)acetyl]pyridine,

4-[2-(2-(6-di-(n-butyl)amino)naphthyl)vinyl]pyridine or

4-[2-(2-naphthyl)ethyl]pyridine.

39. A pharmaceutical formulation, which comprises a compound as claimed in any one of Claims 37 and 38, and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/05817

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/30 C07D213/26 C07D213/32 C07D239/26 C07D277/24
C07D213/61 C07D213/68 A61K31/425 A61K31/4409 A61K31/505
A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BAKER B R ET AL: "IRREVERSIBLE ENZYME INHIBITORS. 181. INHIBITION OF BRAIN CHOLINE ACETYLTRANSFERASE BY DERIVATIVES OF 4-STILBAZOLE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 14, no. 4, 1971, pages 315-322, XP000938518 ISSN: 0022-2623 cited in the application see especially compound 24 the whole document</p> <p style="text-align: center;">--- -/--</p>	1-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

23 July 2001

Date of mailing of the international search report

27/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/05817

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FISHER M H ET AL: "AZAINDOLE ANTHELMINTIC AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 15, no. 11, 1972, pages 1168-1171, XP000938515 ISSN: 0022-2623 cited in the application see compound 24 and whole document</p>	1-36
X	<p>CAVALLITO C J ET AL: "CHOLINE ACETYLTRANSFERASE INHIBITORS. CONFIGURATIONAL AND ELECTRONIC FEATURES OF STYRYLPYRIDINE ANALOGS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 12, no. 1, 5 August 1968 (1968-08-05), pages 134-138, XP000938517 ISSN: 0022-2623 cited in the application see 1-naphthyl compounds I, II and XXV</p>	38, 39
X	<p>GALIAZZO G ET AL: "SYNTHESIS, ELECTRONIC SPECTRA, AND PHOTOISOMERIZATION OF NAPHTHYLPYRIDYLETHYLENES" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, CHEMICAL SOCIETY. LETCHWORTH, GB, 1975, pages 1712-1715, XP001000543 ISSN: 1472-779X cited in the application see examples</p>	38, 39
X	<p>FOZARD A ET AL: "NEW TETRACYCLIC SYSTEMS INCORPORATING THE BENZOQUINOLIZINIUM CATION" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 31, November 1966 (1966-11), pages 3683-3685, XP001000536 ISSN: 0022-3263 cited in the application see compounds X, XI</p>	38, 39
P, X	<p>WO 01 17968 A (SHIONOGI & CO ; KAWASUJI TAKASHI (JP); YOSHINAGA TOMOKAZU (JP)) 15 March 2001 (2001-03-15) see examples I-30, I-31, I-50</p>	38, 39
-/--		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/05817

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>CHANG, C. C. ET AL: "Highly Conjugated Molecules from Dibromonaphthyl Derivatives and 4-Vinylpyridine or 4-Acetoxystyrene by the Heck Reaction" J. ORG. CHEM. (1999), 64(15), 5603-5610 , XP001007512 see compounds b and c, Scheme 1</p>	38
X	<p>SPALLETTI, A. ET AL: "Effect of pyridyl and thienyl groups on the excited state properties of stilbene-like molecules" PROC. - INDIAN ACAD. SCI., CHEM. SCI. (1998), 110(3), 297-310 , XP001000284 see compound 4,1'-PNE</p>	38
X	<p>HOUPIS, IOANNIS N. ET AL: "Ni-catalyzed nucleophilic conjugate additions of Grignard and organozincate reagents to substituted 4-vinylpyridines. General synthesis of phosphodiesterase IV inhibitors." TETRAHEDRON (1998), 54(7), 1185-1195 , XP004106696 see compounds 4d and 5e</p>	38
X	<p>HENDERSON, THERESA R. ET AL: "Inhibition of brain choline acetyltransferase in vivo: (E)-1-methyl-4-(1-naphthylvinyl)-1,2,3,6-tetrahydropyridine hydrochloride (B115), a depot form of a potent inhibitor" TOXICOL. APPL. PHARMACOL. (1991), 107(2), 336-43 , XP001005698 the whole document</p>	38,39
X	<p>GRAY, ALLAN P. ET AL: "Approaches to protection against nerve agent poisoning. (Naphthylvinyl)pyridine derivatives as potential antidotes" J. MED. CHEM. (1988), 31(4), 807-14 , XP001000226 the whole document</p>	38,39
X	<p>SPALLETTI, ANNA ET AL: "Excited state reactivity of aza-aromatics. X. Protonation effect on naphthyl- and phenanthrylpyridylethylenes" Z. PHYS. CHEM. (MUNICH) (1983), 138(2), 199-206 , XP001007013 the whole document</p>	38

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/05817

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	FLEMING, WAYNE C. ET AL: "Anomalous photocyclization of methyl 2-(1-naphthyl)-3-(4-pyridyl)acrylate" J. ORG. CHEM. (1973), 38(26), 4404 , XP001005693 see compound 5c	38
X	CAVALLITO, C. J. ET AL: "Inhibitors of choline acetyltransferase" DRUGS CHOLINERGIC MECH. CNS (CENT. NERV. SYST.), PROC. CONF. (1970), 97-116. EDITOR(S): HEILBRONN, EDITH. PUBLISHER: FOERSVARETS FORSKNINGSSANST., STOCKHOLM, SWED., XP001007086 abstract	38, 39
X	BAKER, BERNARD RANDALL ET AL: "Irreversible enzyme inhibitors. CLXVI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine with 6 substituents and some factors in their cell wall transport" J. MED. CHEM. (1970), 13(1), 82-6 , XP000938516 see compounds 14 and 15	38, 39
X	SCHIELE, C. ET AL: "Preparability of spirobenzothiazoles and 6-ring-N- and -O-heterocyclic spirans. II" TETRAHEDRON (1968), 24(14), 5023-7 , XP001005695 the whole document	38
X	EFANGE S M N ET AL: "MOLECULAR SIZE AND FLEXIBILITY AS DETERMINANTS OF SELECTIVITY IN THE OXIDATION OF N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE ANALOGS BY MONOAMINE OXIDASE A AND B" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 36, no. 9, 1993, pages 1278-1283, XP000938519 ISSN: 0022-2623 cited in the application 8c and 7c	38, 39
	-/--	

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/05817

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEBERNARDIS J F ET AL: "EVALUATION OF THE SIDE ARM OF (NAPHTHYLVINYL)PYRIDINIUM INHIBITORS OF CHOLINE ACETYLTRANSFERASE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 31, no. 1, 1998, pages 117-121, XP001006997 ISSN: 0022-2623 the whole document	38, 39
X	YU L J ET AL: "THE MESOGENIC 6-ALKOXY-2-(2-(4-PYRIDYL)ETHENYL)NAPHTHALE NE HOMOLOGUES" MOLECULAR CRYSTALS AND LIQUID CRYSTALS SCIENCE AND TECHNOLOGY. SECTION A. MOLECULAR CRYSTALS AND LIQUID CRYSTALS, GORDON AND BREACH PUBLISHERS, CH, CH, vol. 265, 1995, pages 89-95, XP001000239 ISSN: 1058-725X the whole document	38
X	PAPPALARDO G ET AL: "RAPPORTO TRA STRUTTURA ED ATTIVITA ANTIBATTERICA DELLE ARILITIOAMIDI" IL FARMACO, ROME, IT., vol. 21, no. 10, 1966, pages 740-748, XP000912176 the whole document	38, 39
X	US 4 016 195 A (PINTSCHOVIVUS ULRICH ET AL) 5 April 1977 (1977-04-05) see column 9	38
X	PATENT ABSTRACTS OF JAPAN vol. 016, no. 234 (C-0945), 29 May 1992 (1992-05-29) & JP 04 046987 A (SHIN ETSU CHEM CO LTD), 17 February 1992 (1992-02-17) see formula II abstract	38
X	US 4 839 353 A (HOSOI MASAOKI ET AL) 13 June 1989 (1989-06-13)	38, 39
A	the whole document	1-36
A	WO 00 08006 A (BAKER STEPHEN RICHARD ; LILLY CO ELI (GB); GOLDSWORTHY JOHN (GB); H) 17 February 2000 (2000-02-17) the whole document	1-36, 38, 39

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01 05817

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1-36(partly), 37, 38-39(partly)

Present claims 38,39 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds wherein E is as in claim 12. As can be seen from the Search Report, many documents were found even with this limitation, and the list given in the Search Report is not exhaustive.

Claim 37 is unclear in scope (Article 6 PCT)

Present claims 1-35 relate to a product defined by reference to a desirable characteristic or property, namely its use in the treatment of a condition indicating treatment with a GluR6 antagonist. These claims lack clarity (Article 6 PCT), as it is only possible to claim such functional definitions if instructions, in the form of experimental tests or any testable criteria are available from the patent document or from the common general knowledge allowing the recognition of which conditions fall within the functional definition. In the present case, the search was limited to those therapeutic application listed in the description, pages 4,5, and for claims 1-35 and 36, for those structures as stated above for claims 38 and 39.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/05817

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0117968 A	15-03-2001	AU 6731100 A	10-04-2001
US 4016195 A	05-04-1977	DE 2060228 A	15-06-1972
		US 3957846 A	18-05-1976
		BE 776415 A	08-06-1972
		CA 982128 A	20-01-1976
		CH 579665 B	15-09-1976
		CH 1763771 A	15-03-1976
		DD 97904 A	20-05-1973
		FR 2117470 A	21-07-1972
		GB 1379051 A	02-01-1975
		IT 943766 B	10-04-1973
		NL 7116652 A	12-06-1972
		US 3822305 A	02-07-1974
JP 04046987 A	17-02-1992	JP 2731971 B	25-03-1998
US 4839353 A	13-06-1989	EP 0264883 A	27-04-1988
		JP 1131157 A	24-05-1989
WO 0008006 A	17-02-2000	AU 5184599 A	28-02-2000
		EP 1104413 A	06-06-2001